Breast cancers can be characterized as HR positive (either single or double HR positive), human epidermal growth factor receptor 2 (HER2) positive, or triple negative, and the type of cancer determines the anticancer treatment modalities and also predicts tumor sensitivity to pharmacological therapies as well as patient prognosis. This evidence concerns the gene ERBB2 and neoplasm.